A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)

Clinical trial NCT03913143 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03913143
Sponsor: ProQR Therapeutics
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Leber Congenital Amaurosis 10 Blindness Leber Congenital Amaurosis Vision Disorders Sensation Disorders Neurologic Manifestations Eye Diseases Eye Diseases, Hereditary Eye Disorders Congenital Retinal Disease

Start date: 2019-04-04
Primary completion: 2022-01-31
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.